# Discussing therapeutic objectives and decision making



# **Clinical suitability**

Scoliosis, AAV 9 Ab, liver, renal, cardiac function, full blood count



#### **Individual Goals**

Lived experience and variability, response may not be the same as clinical trials



## How is the treatment delivered

Frequency, route of administration



# **Expected outcome**

Determinants include age/disease duration, clinical status/motor function, prior therapy




#### **Risks**

There may be higher risk of side effects with combination therapy



### How response will be evaluated after treatment



### Small molecule splicing modifiers



#### Antisense oligonucleotide splicing modifier



4 Loading Intrathecal in 2 months



Gene replacement / gene therapy



Single dose intravenous / intrathecal

# Requirements for ongoing care

Multidisciplinary care, therapy and monitoring



#### Cost and access

Differs between health systems